Ottawa, Ontario – (Marketwired – November 3, 2016) – Tetra Bio-Pharma Inc. (“TetraBio” or the “Company”) (CSE:TBP) through its subsidiary, PhytoPain Pharma Inc. (“PPP”), is pleased to announce that it has signed a Supply Agreement with Access to Cannabis for Medical Purpose Regulations (“ACMPR”) licensed producer Aphria Inc. (“Aphria”) (TSX-V: APH or USOTCQB: APHQF) for the supply of dried medical cannabis as an Active Pharmaceutical Ingredient (API) for PPP’s inhalation cannabis product PPP001. PPP001 is a medical marijuana product that the company is developing as a prescription controlled drug for inhalation using a fully assembled titanium pipe.